A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced.
Fatty liver disease
FATTY LIVER DISEASE
NewsExposure to High-Fat Diet in Womb and During Breastfeeding Linked to Liver Disease
A child exposed to a mother’s high-fat diet while in the womb and breastfeeding is at greater risk of developing non-alcoholic fatty liver disease (NAFLD)…
Recent Posts
- One of my superpowers for MASH is defiance in the name of compliance
- Canada approves Livmarli oral tablets for Alagille itching
- New experimental therapy enters early human testing for hepatitis B
- Risk of PSC recurrence 4 times higher with living donor transplant: Study
- Early detection highlighted in this year’s Rare Liver Diseases Month